Literature DB >> 20220120

Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.

John G Nutt1, Kathy A Chung, Nicholas H G Holford.   

Abstract

OBJECTIVE: To clinically characterize the temporal relationship between dyskinesia and the antiparkinsonian response when dyskinesia first emerges during long-term levodopa therapy and to determine if it is consistent with the hypothesized mechanism by which dyskinesia develops.
METHODS: Dyskinesia and the antiparkinsonian response to levodopa during 2-hour levodopa infusions were monitored at intervals through the first 4 years of long-term levodopa therapy in 20 subjects with idiopathic Parkinson disease (PD) and previously untreated with levodopa. The onset and offset of the antiparkinsonian response and dyskinesia were compared when dyskinesia first appeared during the 4 years. The findings were compared to 20 subjects with PD on long-term levodopa with dyskinesia and motor fluctuations.
RESULTS: The onset and offset of the antiparkinsonian response and dyskinesia generally coincided when dyskinesia first appeared during the 4 years and did not suggest any temporal dissociation of the 2 responses. Further, the latency to the onsets of dyskinesia and the antiparkinsonian response tended to shorten during long-term levodopa therapy, suggesting that both responses were sensitized by long-term levodopa.
CONCLUSIONS: The similar onsets and offsets of the antiparkinsonian response and dyskinesia when dyskinesia first appears are not consistent with the postulated progressive decrease in threshold for dyskinesia during long-term levodopa therapy. Other mechanisms for the development of dyskinesia need to be considered.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20220120      PMCID: PMC2865731          DOI: 10.1212/WNL.0b013e3181d90050

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  27 in total

1.  The dopamine transporter: importance in Parkinson's disease.

Authors:  John G Nutt; Julie H Carter; Gary J Sexton
Journal:  Ann Neurol       Date:  2004-06       Impact factor: 10.422

2.  Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).

Authors:  C Warren Olanow; Philippe Damier; Christopher G Goetz; Thomas Mueller; John Nutt; Olivier Rascol; Alexandru Serbanescu; Frieda Deckers; Hermann Russ
Journal:  Clin Neuropharmacol       Date:  2004 Mar-Apr       Impact factor: 1.592

3.  The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.

Authors:  B J Snow; L Macdonald; D Mcauley; W Wallis
Journal:  Clin Neuropharmacol       Date:  2000 Mar-Apr       Impact factor: 1.592

4.  Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy.

Authors:  E Melamed; V Bitton; O Zelig
Journal:  Clin Neuropharmacol       Date:  1986       Impact factor: 1.592

5.  Aromatic amino acids and modification of parkinsonism.

Authors:  G C Cotzias; M H Van Woert; L M Schiffer
Journal:  N Engl J Med       Date:  1967-02-16       Impact factor: 91.245

6.  Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.

Authors:  J W Langston; P Ballard
Journal:  Can J Neurol Sci       Date:  1984-02       Impact factor: 2.104

7.  The Bradykinesia Akinesia Incoordination Test (BRAIN TEST), an objective and user-friendly means to evaluate patients with parkinsonism.

Authors:  C N Homann; K Suppan; K Wenzel; G Giovannoni; G Ivanic; S Horner; E Ott; H P Hartung
Journal:  Mov Disord       Date:  2000-07       Impact factor: 10.338

Review 8.  Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?

Authors:  Agnès Nadjar; Charles R Gerfen; Erwan Bezard
Journal:  Prog Neurobiol       Date:  2008-09-30       Impact factor: 11.685

9.  Young onset Parkinson's disease.

Authors:  N Quinn; P Critchley; C D Marsden
Journal:  Mov Disord       Date:  1987       Impact factor: 10.338

10.  Evolution of the response to levodopa during the first 4 years of therapy.

Authors:  John G Nutt; Julie H Carter; Eric S Lea; Gary J Sexton
Journal:  Ann Neurol       Date:  2002-06       Impact factor: 10.422

View more
  12 in total

Review 1.  Molecular imaging of levodopa-induced dyskinesias.

Authors:  Flavia Niccolini; Lorenzo Rocchi; Marios Politis
Journal:  Cell Mol Life Sci       Date:  2015-02-15       Impact factor: 9.261

2.  Nigral dopamine loss induces a global upregulation of presynaptic dopamine D1 receptor facilitation of the striatonigral GABAergic output.

Authors:  Shengyuan Ding; Li Li; Fu-Ming Zhou
Journal:  J Neurophysiol       Date:  2014-12-30       Impact factor: 2.714

Review 3.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

4.  Assessment of Parkinson's disease levodopa-induced dyskinesia: a qualitative research study.

Authors:  William R Lenderking; Sally Mannix; Jennifer Petrillo; Christopher Kenney; Amanda Landrian; Anette-Eleonore Schrag
Journal:  Qual Life Res       Date:  2015-02-06       Impact factor: 4.147

5.  Serotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice.

Authors:  Li Li; Guozhen Qiu; Shengyuan Ding; Fu-Ming Zhou
Journal:  Brain Res       Date:  2012-11-15       Impact factor: 3.252

6.  Parallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice.

Authors:  L Li; F-M Zhou
Journal:  Neuroscience       Date:  2013-01-26       Impact factor: 3.590

7.  Analysis of factors associated with brittle response in patients with Parkinson's disease.

Authors:  Yayun Yan; Yanyan Li; Xiufeng Liu; Liyao Zhang; Lu Wang; Ying Chang
Journal:  Ann Clin Transl Neurol       Date:  2020-04-30       Impact factor: 4.511

8.  Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease.

Authors:  Syam Krishnan; Krishnakumar Kesava Pisharady
Journal:  Ann Indian Acad Neurol       Date:  2017 Jul-Sep       Impact factor: 1.383

Review 9.  PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.

Authors:  Gennaro Pagano; Tayyabah Yousaf; Marios Politis
Journal:  Curr Neurol Neurosci Rep       Date:  2017-10-03       Impact factor: 5.081

10.  Aromatic L-Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease.

Authors:  John G Nutt; Carolin Curtze; Amie Hiller; Shannon Anderson; Paul S Larson; Amber D Van Laar; R Mark Richardson; Marin E Thompson; Alexander Sedkov; Mika Leinonen; Bernard Ravina; Krystof S Bankiewicz; Chadwick W Christine
Journal:  Mov Disord       Date:  2020-03-09       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.